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Grabbing Amphiregulin  
by the Tail to Better Understand 
Keratinocyte Growth
John T. Seykora1
Amphiregulin (AReG) is an important regulator of cellular growth in keratinocytes, 
carcinomas, and hyperproliferative epidermal disorders, including psoriasis. Stoll 
and colleagues present data suggesting that the cytoplasmic carboxy-terminal 
domain of amphiregulin plays an important role in regulating autocrine keratino-
cyte growth through the epidermal growth factor receptor. These observations 
raise novel and interesting biological questions regarding the function of the cyto-
plasmic c-terminal region of AReG.
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Amphiregulin (AREG), a member of 
the EGFR ligand family, is important for 
regulating keratinocyte growth (Stoll 
et al., 2010, this issue). In vivo studies 
of transgenic mice overexpressing 
AREG in the epidermis demonstrate a 
complex yet psoriasiform phenotype 
including epidermal hyperplasia, cuta-
neous inflammation, and arthritis (Cook 
et al., 1997). Ligand-dependent signaling 
through EGFR in keratinocytes is com-
plex, because these cells can produce 
at least five members of the EGFR ligand 
family, including AREG, epiregulin, 
heparin-binding EGF-like growth factor, 
betacellulin, and transforming growth 
factor-α  (Coffey et al., 1987; Cook et al., 
1991; Hashimoto et al., 1994; Shirakata 
et al., 2000; Strachan et al., 2001). The 
expression of multiple EGFR ligands in 
keratinocytes raises a question regard-
ing the specific biological role of AREG 
in regulating keratinocyte growth. If 
AREG plays a specific role in regulating 
keratinocyte growth, then what struc-
tural motifs of AREG are responsible for 
this important biological effect? The data 
presented by Stoll et al. (2010) provide 
insights into this complex scenario.
The AREG (also known as 
schwannoma-derived growth factor) 
gene is located on human chromosomal 
band 4q13.3 and yields a 1.4-kb tran-
script composed of six exons that can 
produce a 252–amino acid (aa) trans-
membrane glycoprotein. This polypep-
tide is also known as the pro-form of 
AREG (Pro-AREG). Pro-AREG is com-
posed of multiple domains, including a 
signal sequence (aa 1–19), an N-terminal 
domain (aa 20–101), an EGF-like 
domain (aa 102–184), a membrane stalk 
(aa 185–198), a transmembrane domain 
(aa 199–221), and a cytoplasmic domain 
(aa 222–252).
Transmembrane EGFR ligands such 
as AREG are released from their mem-
brane anchors by metalloproteinases 
and ADAM family proteases; this pro-
cessing adds another layer of regulation 
(Lu et al., 2009; Sternlicht et al., 2005). 
In fact, ADAM17-null mice, to some 
extent, phenocopy EGFR-null mice 
(Sternlicht et al., 2005). As expected, 
proteolysis of AREG results in four mem-
brane-bound and four soluble isoforms 
(Brown et al., 1998). Hypothetically, 
each of these eight isoforms could 
have a unique signaling potential; such 
molecular diversity raises the possibility 
of complex signaling paradigms.
To better understand the role of 
AREG in regulating keratinocyte growth, 
Stoll and colleagues (2010) utilized a 
knockdown approach with lentiviruses 
that express a tetracycline-inducible 
small hairpin RNA (shRNA) targeting 
AREG. Keratinocytes transduced with 
this lentivirus downregulated AREG 
mRNA and cell-associated AREG pro-
tein levels by 83 and 71%, respective-
ly, and shed AREG by more than 95%, 
all in a doxycycline-dependent man-
ner. Previous work by this group has 
shown that AREG antibodies can block 
the autocrine-stimulated ERK phos-
phorylation and keratinocyte prolifera-
tion induced by shed AREG (Kansra et 
al., 2004, 2005). The AREG-dependent 
growth of these keratinocytes was also 
inhibited by metalloproteinase inhibi-
tors and ErbB tyrosine kinase inhibitors, 
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which block ErbB signaling upon ligand 
engagement. Induction of the AREG 
shRNA reduced keratinocyte growth 
by 86% and strongly induced the levels 
(>100-fold) of differentiation markers 
such as keratin 1, keratin 10, involucrin, 
and loricrin. These results demonstrate 
that these engineered keratinocytes 
need AREG to promote growth and 
inhibit differentiation, as do normal 
human keratinocytes.
These observations raised an 
interesting question: is keratinocyte 
growth inhibition secondary to AREG 
shRNA knockdown similar to that 
induced by AREG neutralizing anti-
bodies? To address this question, the 
authors asked whether exogenous appli-
cation of soluble EGFR family ligands 
could rescue the effects of AREG shRNA 
knockdown. These experiments led to a 
surprising result—the addition of soluble, 
recombinant EGF, heparin-binding EGF, 
epiregulin and/or transforming growth 
factor-α, and even AREG at 100 ng/ml, 
could not revert the growth inhibition 
caused by the knockdown of AREG via 
shRNA. As expected, exogenous appli-
cation of EGFR ligands overcame the 
growth inhibition induced by neutralizing 
anti-AREG antibodies. Interestingly, the 
addition of EGFR ligands to keratinocytes 
subjected to AREG knockdown resulted 
in the appearance of large, flattened 
cells, suggesting that EGFR signaling may 
be redirected toward a prodifferentiation 
pathway when AREG is absent.
The experimental differences between 
the effects of AREG-blocking antibodies 
and AREG knockdown on EGFR ligand 
exposure raised the hypothesis that cell-
associated AREG may signal differently 
than soluble AREG. To explore this 
further, the investigators derived kerati-
nocytes that stably expressed the AREG 
extracellular domain (aa 1–184) or the 
transmembrane full-length AREG (aa 
1–252) in conjunction with the tet-induc-
ible AREG shRNA. It should be noted 
that the AREG shRNA targets a sequence 
in the 3′ untranslated region, which is 
not present in the lentiviral constructs 
used to express the AREG extracellular 
domain or full-length forms.
Both cell lines grew similarly in the 
absence of tetracycline; however, tetracy-
cline-induced AREG knockdown inhib-
ited growth of keratinocytes expressing 
the lentiviral extracellular domain of 
AREG but not the transmembrane form 
of AREG. In addition, the lentiviral trans-
membrane form of AREG inhibited the 
expression of differentiation markers that 
were induced by tetracycline in the kera-
tinocytes expressing AREG shRNA.
These data support the hypothesis 
that the transmembrane form of AREG is 
critical for mediating autocrine keratino-
cyte proliferation. Interestingly, the data 
also show that ERK phosphorylation 
was more strongly inhibited by anti-
AREG antibodies, whereas keratinocyte 
growth was more strongly inhibited by 
AREG shRNAs, suggesting that AREG 
may be involved in “geographically” 
distinct intracellular signaling path-
ways that regulate keratino cyte growth 
and differentiation. The critical role of 
the transmembrane domain of AREG 
in regulating keratinocyte growth raises 
important questions regarding biologic 
mechanism. Future questions relevant 
to this work could include the follow-
ing: (i) how does the domain encom-
passing aa 185–252 of AREG regulate 
its cell surface distribution?; (ii) does 
this C-terminal region of AREG regulate 
EGFR receptor clustering and signaling?; 
and (iii) does this portion of AREG mani-
fest independent signaling properties or 
influence EGFR complex endocytosis? 
Experiments addressing these questions 
should provide fresh insights into the 
paradigm of AREG biology.
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Figure 1. areG signaling in keratinocytes. ADAM proteases can cleave AREG to produce extracellular 
and intracellular components. The C-terminal cytoplasmic region of AREG (small red oval) appears to 
be important for EGFR-mediated signaling and regulates keratinocyte growth and differentiation. The 
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Protein Kinase c/Mitogen-Activated 
Protein Kinase Signaling in 
Keratinocyte Differentiation control
Mitchell F. Denning1
Proper epidermal keratinocyte differentiation, which is necessary for cutaneous 
barrier function, is altered in many common skin diseases. Keratinocyte 
differentiation is controlled by a complex signaling network involving multiple 
members of the protein kinase c and mitogen-activated protein kinase signaling 
kinases. Using an RnA interference knockdown approach, Adhikary et al. identified 
essential nodes in this signaling network, revealing remarkable kinase specificity.
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Most of us take differentiation of our 
epidermis for granted. Our skin reliably 
provides adequate barrier function and 
the aesthetic appearance associated 
with a normal, healthy skin. For a signif-
icant number of people, however, epi-
dermal differentiation does not proceed 
normally, and their skin is a chronic 
source of irritation, inflammation, and 
aggravation. Several of the most com-
mon skin diseases, including eczema 
(atopic dermatitis), ichthyosis (vul-
garis, lamellar, and X-linked), and pso-
riasis, are associated with fundamental 
defects in epidermal differentiation. 
These defects are not always simply a 
response to an underlying disease pro-
cesses; often they are pathogenic. For 
example, ichthyosis vulgaris and atopic 
dermatitis are linked to loss-of-function 
mutations in the intermediate filament 
bundling protein filaggrin (Smith et al., 
2006; Palmer et al., 2006). Because 
disruption of epidermal differentiation 
is responsible for a considerable por-
tion of the morbidity associated with 
these diseases, a better understand-
ing of the basic processes that control 
keratinocyte differentiation is needed to 
achieve pharmacological improvement 
for the tens of millions of people who 
suffer from them.
Adhikary et al. (2010, this issue) 
focus on the transcriptional regula-
tion of involucrin, a constituent of the 
cornified envelope and resident of the 
epidermal differentiation complex 
on chromosome 1q21. Involucrin is 
expressed in the spinous and granu-
lar layers of the epidermis and is tran-
scriptionally upregulated by a variety 
of differentiating agents, e.g., calcium, 
12-O-tetradecanoylphorbol-13-acetate 
(TPA), vitamin D, and (−)-epigallocate-
chin-3-gallate (EGCG). Although invo-
lucrin-null mice appear normal and 
have no obvious skin phenotype (Djian 
et al., 2000), involucrin induction is 
part of the coordinated transcriptional 
response during keratinocyte differ-
entiation, and it can be considered 
a prototypical keratinocyte differen-
tiation marker that shares regulatory 
overlap with many genes residing in 
the epidermal differentiation complex. 
Thus, involucrin is a reasonable surro-
gate for keratinocyte differentiation. In 
addition, several of the critical signal-
ing kinases identified as important for 
involucrin induction are also important 
for morphological changes that accom-
pany differentiation.
The findings of Adhikary et al. (2010) 
help delineate a signaling network 
involving protein kinase C (PKC)-δ, 
MEKK-1, MEK-3, MEK-6, and p38-δ as 
essential to activate activating protein 
1 nuclear translocation, DNA binding, 
and involucrin gene expression by mul-
tiple differentiation stimuli (Figure 1). 
PKC-η is also implicated in involucrin 
induction by TPA, but not Ca2+ or EGCG. 
PKC isoforms can activate mito-
gen-activated protein kinase (MAPK) 
pathways via multiple mechanisms, 
and overexpression of both PKC-δ and 
